Sino Biopharm is facing declining profit/stagnant revenue due to low COVID-19 vaccine demand and VBP. Lack of trust and corporate governance deficiencies hinder the market from granting high valuation
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.